From: Overexpression of CCDC69 activates p14ARF/MDM2/p53 pathway and confers cisplatin sensitivity
 | Chemo-sensitive | Chemo-resistant | p-value |
---|---|---|---|
No. of patients | 97 | 38 | Â |
FIGO Stage |  |  | P = 0.2011 |
 II | 9 (9.3) | 1 (2.6) |  |
 III | 77 (79.4) | 35 (92.1) |  |
 IV | 11 (11.3) | 2 (5.3) |  |
WHO Grade |  |  | P = 0.6123 |
 2 | 15 (15.5) | 4 (10.5) |  |
 3 | 81 (83.5) | 33(86.8) |  |
 Unknown | 1 (1.0) | 1(2.6) |  |
Residual disease |  |  | P = 0.0708 |
 No Macroscopic disease | 27 (27.8) | 5 (13.2) |  |
 1–10 mm | 39 (40.2) | 23 (60.5) |  |
 11–20 mm | 7 (7.2) | 2 (5.3) |  |
  > 20 mm | 16 (16.5) | 6 (15.8) |  |
 NA | 8 (8.2) | 2 (5.3) |  |
 Progression Free Survival(median, mons) | 19.91 (3.3–87) | 9.185 (2.3–15.2) | P < 0.0001 |
 Overall Survival (median, mons) | 41.03 (8.8–125.6) | 32.835 (6.7–66) | P = 0.0047 |